51062-15-8

Basic information

• Product Name: 1(P-METHOXYPHENYL)-3-BUTYLAMINE
• Synonyms: 1(P-METHOXYPHENYL)-3-BUTYLAMINE;1-(4'-METHOXYPHENYL)-3-BUTYLAMINE;4-(4-Methoxyphenyl)-2-butylamine;4-Methoxy-α-methylbenzenepropan-1-amine;Einecs 256-939-3;TIMTEC-BB SBB010641;ASINEX-REAG BAS 03220611;4-(4-METHOXYPHENYL)BUTYL-2-AMINE
• CAS NO: 51062-15-8
• Molecular Formula: C₁₁H₁₇NO
• Molecular Weight: 179.26
• EINECS: 256-939-3
• Mol File: 51062-15-8.mol

Chemical Properties

• Boiling Point: 276.6°Cat760mmHg
• Flash Point: 116.4°C
• Appearance: /
• Density: 0.977g/cm³
• Vapor Pressure: 0.00474mmHg at 25°C
• Refractive Index: 1.514
• PKA: 10.67±0.35(Predicted)
• CAS DataBase Reference: 1(P-METHOXYPHENYL)-3-BUTYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1(P-METHOXYPHENYL)-3-BUTYLAMINE(51062-15-8)
• EPA Substance Registry System: 1(P-METHOXYPHENYL)-3-BUTYLAMINE(51062-15-8)

Safety Data

• RIDADR: UN2735
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 51062-15-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1(P-METHOXYPHENYL)-3-BUTYLAMINE is used as a potential treatment for neurological and psychiatric disorders such as depression and attention deficit hyperactivity disorder (ADHD) due to its pharmacological effects as a norepinephrine-dopamine reuptake inhibitor and a releasing agent for serotonin, norepinephrine, and dopamine.
Used in Recreational Drug Industry:
1(P-METHOXYPHENYL)-3-BUTYLAMINE has been investigated for its potential as a recreational drug, with reports of its use in designer drug formulations. However, its safety and legal status are not well-established, and it is not approved for medical use in most countries.

InChI:InChI=1/C11H17NO/c1-9(12)3-4-10-5-7-11(13-2)8-6-10/h5-9H,3-4,12H2,1-2H3/t9-/m1/s1

Upstream product

• 104-20-1 4-(4-methoxyphenyl)-2-butanone 
• 123-11-5 4-methoxy-benzaldehyde 
• 943-88-4 4-(p-methoxyphenyl)-3-butene-2-one 
• 33966-50-6 SEC-BUTYLAMINE 
• 128156-33-2 4-(4-Methoxy-benzyl)-3-methyl-2H-isoxazol-5-one 
• 1222558-29-3 [((E)-4-(4-methoxyphenyl)but-3-en-2-ylidene)amino]hydroxide 
• 15118-58-8 4-(4-methoxy-phenyl)-2-methyl-butyric acid amide 

Downstream Products

• 1237755-56-4 C₂₀H₂₅NO₄ 
• 1237756-01-2 C₁₉H₂₀F₃NO₂ 
• 1237756-02-3 C₁₉H₂₀N₂O₂ 
• 1237756-00-1 C₁₉H₂₃NO₃ 
• 86244-91-9 (+)-4'-[2-(ethoxy)ethoxy]-2-{[3(4-methoxyphenyl)-1-methylpropyl]amino}-3'-(methylthio)acetophenone hydrobromide 
• 66264-76-4 4'-hydroxy-2-{[3-(4-methoxyphenyl)-1-methylpropyl]amino}-3'-(methylthio)acetophenone 4'-benzoate hydrobromide 
• 147010-41-1 ethyl N-[1-(4-methoxyphenyl)-3-butyl]oxamate 

Relevant articles and documents

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

Buttressing Salicylaldehydes: A Multipurpose Directing Group for C(sp3)?H Bond Activation

A palladium-catalyzed reaction of primary amines with iodoarenes produces γ-arylated primary amines. A bulky salicylaldehyde, which is marked as easily available, installable, removable, and recoverable, plays a key role in directing palladium to site-selectively activate the C?H bond located γ to the amino group.

Catalytic C(sp3)?H Arylation of Free Primary Amines with an exo Directing Group Generated In Situ

Herein, we report the palladium-catalyzed direct arylation of unactivated aliphatic C?H bonds in free primary amines. This method takes advantage of an exo-imine-type directing group (DG) that can be generated and removed in situ. A range of unprotected aliphatic amines are suitable substrates, undergoing site-selective arylation at the γ-position. Methyl as well as cyclic and acyclic methylene groups can be activated. Furthermore, when aniline-derived substrates were used, preliminary success with δ-C?H arylation was achieved. The feasibility of using the DG component in a catalytic fashion was also demonstrated.

Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease

The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

Hydrogenolysis of 3-methyl-4-phenylmethyl-5(2H)-isoxazolone derivatives: A reinvestigation

Hydrogenolysis of 3-methyl-4-phenylmethyl-5(2H)-isoxazolone (2a) and its derivatives 2b-e, 5a-e, 6a-e and 9a,b have been carried out over Pd/C and Raney-nickel.The products have been isolated and characterized.The intermediate products of hydrogenolysis of 2b-e have been trapped and simultaneous cleavage of N - O and C - C bonds in 9a,b has been suggested to explain the formation of the hydrogenolysis products 10a,b and 3a,b.

Alpha-(aminoalkyl-4-hydroxy-3-(alkylthio)benzenemethanols

Alpha-(aminoalkyl)-4-hydroxy-3-(alkylthio)benzenemethanols useful as intermediates and as antihypertensive agents are prepared by reduction of the corresponding aminoalkyl 4-hydroxy-3-(alkylthio)phenyl ketones.

Derivatives related to betaxolol with α- and β-adrenergic activities

The paper describes the synthesis and the pharmacological evaluation of some derivatives of betaxolol, all with an N-aralkylamine instead of the tertiobutylamine. These compounds have been tested for β1-adrenergic receptor antagonism on guinea pig atria, β2-adrenergic receptor antagonism on guinea pig trachea and α-adrenergic blocking activity on rat aorta. Compound U12 with a marked α-blocking activity and compound R8 with a β1/α ratio = 1 were selected for a haemodynamic study in the dog. The decrease in cardiac work and the diminution of total peripheral resistance exhibited by U12 are consistent with a dual α/β-blocking agent. Finally, structure-activity relationships are discussed.

α-{[(Arylalkyl)amino]alkyl}-4-hydroxy-3-(lower-alkylsulfinyl)benzenemethanols

The instant invention is directed to α-(aminoalkyl)-4-hydroxy-3-(alkylsulfinylbenzenemethanols and to a method of utilizing the compounds for reducing blood pressure in mammals.